# Rapid Response Program – Funded Projects

| Program Year | Principal Applicant | Project Title |
|---|---|---|
| 2019 | Yasser Iturria Medina | Personalizing Treatments in Parkinson's Disease via Data-Driven Therapeutic 'Fingerprints' |
| 2019 | Holger Wille | Rationally designed, structure-based vaccine candidates targeting synucleinopathies. |
| 2019 | Martin Lévesque | Activation of the small GTPase Rin to rescue alpha-synuclein neuropathology |
| 2019 | Jonathan Brouillette | The soluble fragment of neuroligin-1 as a blood biomarker of prodromal Alzheimer's disease |
| 2019 | Martin Lévesque | Modulation of SLP-2 expression to protect against alpha-synuclein neuropathology |
| 2019 | Anurag Tandon | Nanobody gene expression for the treatment of synucleinopathies |
| 2020 | Jean-Pierre Julien | AAV-mediated delivery of single chain antibody to target TDP-43 proteinopathy |
| 2020 | Matthew Macauley | Modulating Microglia through the Alzheimer's Disease Related Gene CD33 |
| 2020 | Pedro Rosa Neto | Multicenter validation of high-performance plasma phospho-tau biomarkers for the diagnosis of Alzheimer's disease. |
| 2024 | Marco Prado | Testing the efficacy of an amyloid vaccine on high-level cognition in a new genetic-risk model of Alzheimer's disease |
| 2024 | Margaret Fahnestock | Delivering therapeutics across the blood brain barrier |
| 2024 | Joel Watts | Humanized mouse models targeting alpha-synuclein to improve drug discovery |
| 2024 | Martin Levesque | Advancing Neuroimaging Biomarkers for Parkinson's Disease: Targeting Pathological Alpha-Synuclein with Immuno-Radioligand Imaging |
| 2024 | Paul Fraser | Advancing a SUMO2-based biologic for the treatment of neurodegenerative diseases |
| 2025 | Etienne de Villers-Sidani | Development and validation of a digital biomarker-based tool for the early screening and monitoring of Alzheimer's Disease |
| 2025 | Carmela Tartaglia | Bringing precision medicine to neurodegenerative disease |
| 2025 | Cheryl Wellington | Generation of Canadian reference intervals for plasma phosphorylated tau-217 |

| 2025 | Stuart Fogel | Targeted enhancement of sleep to restore sleep-dependent memory consolidation in prodromal dementia |
| --- | --- | --- |
| 2025 | Philippe Huot | Characterization of novel GlyT1 inhibitors for the treatment of Parkinson's disease |
| 2025 | Amanpreet Badhwar | Translational integration of blood-based biomarkers and virtual reality cognitive testing for enhanced subtyping of subjective cognitive decline |
| 2025 | Peter St George-Hyslop | Antisense oligonucleotide-mediated therapeutic knockdown of the ABI3 Alzheimer risk gene |